265 related articles for article (PubMed ID: 28840598)
1. Therapeutic monoclonal antibodies in combination with pomalidomide can overcome refractoriness to both agents in multiple myeloma: A case-based approach.
Baertsch MA; Hundemer M; Hillengass J; Goldschmidt H; Raab MS
Hematol Oncol; 2018 Feb; 36(1):258-261. PubMed ID: 28840598
[TBL] [Abstract][Full Text] [Related]
2. Novel immunomodulatory compounds in multiple myeloma.
Saini N; Mahindra A
Expert Opin Investig Drugs; 2013 Feb; 22(2):207-15. PubMed ID: 23265189
[TBL] [Abstract][Full Text] [Related]
3. Pomalidomide in heavily pretreated refractory multiple myeloma: a case report.
Palmas A; Piras G; Uras A; Asproni R; Murineddu M; Monne M; Stradoni R; Latte G
Future Oncol; 2017 Feb; 13(5s):7-9. PubMed ID: 28116939
[TBL] [Abstract][Full Text] [Related]
4. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
Offidani M; Corvatta L; Caraffa P; Leoni P; Pautasso C; Larocca A; Palumbo A
Expert Rev Anticancer Ther; 2014 May; 14(5):499-510. PubMed ID: 24738833
[TBL] [Abstract][Full Text] [Related]
5. Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma.
Conticello C; Parisi M; Romano A; Calafiore V; Ancora F; La Fauci A; Consoli ML; Di Raimondo F
Future Oncol; 2017 Feb; 13(5s):3-6. PubMed ID: 28116941
[TBL] [Abstract][Full Text] [Related]
6. Pomalidomide: when expectations are understated.
Di Raimondo F; Conticello C
Future Oncol; 2017 Feb; 13(5s):1-2. PubMed ID: 28116940
[No Abstract] [Full Text] [Related]
7. Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma.
Mark TM; Coleman M; Niesvizky R
Leuk Res; 2014 May; 38(5):517-24. PubMed ID: 24690110
[TBL] [Abstract][Full Text] [Related]
8. Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma.
Hussain MJ; Robinson MM; Hamadeh I; Arnall J; Bhutani M; Atrash S; Friend R; Pineda-Roman M; Symanowski JT; Usmani SZ; Voorhees PM
Br J Haematol; 2019 Jul; 186(1):140-144. PubMed ID: 30536372
[No Abstract] [Full Text] [Related]
9. Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.
Highsmith KN; Chen SE; Horowitz S
Pharmacotherapy; 2014 Sep; 34(9):927-40. PubMed ID: 25044413
[TBL] [Abstract][Full Text] [Related]
10. The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents.
Gavriatopoulou M; Kastritis E; Ntanasis-Stathopoulos I; Fotiou D; Roussou M; Migkou M; Ziogas DC; Kanellias N; Terpos E; Dimopoulos MA
Blood; 2018 Jan; 131(4):464-467. PubMed ID: 29167176
[No Abstract] [Full Text] [Related]
11. Pomalidomide for patients with multiple myeloma.
Gras J
Drugs Today (Barc); 2013 Sep; 49(9):555-62. PubMed ID: 24086951
[TBL] [Abstract][Full Text] [Related]
12. Pomalidomide combinations are a safe and effective option after daratumumab failure.
Brioli A; Gengenbach L; Mancuso K; Binder M; Ernst T; Heidel FH; Stauch T; Zamagni E; Hilgendorf I; Hochhaus A; Engelhardt M; von Lilienfeld-Toal M
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6569-6574. PubMed ID: 36781500
[TBL] [Abstract][Full Text] [Related]
13. Pomalidomide for multiple myeloma.
Fouquet G; Bories C; Guidez S; Renaud L; Herbaux C; Javed S; Facon T; Leleu X
Expert Rev Hematol; 2014 Dec; 7(6):719-31. PubMed ID: 25265911
[TBL] [Abstract][Full Text] [Related]
14. Pooled analysis of pomalidomide for treating patients with multiple myeloma.
Sun JJ; Zhang C; Zhou J; Yang HL
Asian Pac J Cancer Prev; 2015; 16(8):3163-6. PubMed ID: 25921115
[TBL] [Abstract][Full Text] [Related]
15. [Novel agents in multiple myeloma treatment].
Ito S
Rinsho Ketsueki; 2015 Oct; 56(10):2066-73. PubMed ID: 26458446
[TBL] [Abstract][Full Text] [Related]
16. [Pomalidomide for multiple myeloma].
Fouquet G; Macro M; Decaux O; Fohrer C; Guidez S; Demarquette H; Le Grand C; Prodhomme C; Renaud L; Bories C; Herbaux C; Karlin L; Roussel M; Benboubker L; Hulin C; Arnulf B; Leleu X
Rev Med Interne; 2015 Sep; 36(9):613-8. PubMed ID: 26257103
[TBL] [Abstract][Full Text] [Related]
17. Daratumumab vs pomalidomide for the treatment of relapsed/refractory multiple myeloma: A cost-effectiveness analysis.
Gong CL; Studdert AL; Liedtke M
Am J Hematol; 2019 Mar; 94(3):E68-E70. PubMed ID: 30536952
[No Abstract] [Full Text] [Related]
18. New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.
van de Donk NW; Lokhorst HM
Expert Opin Pharmacother; 2013 Aug; 14(12):1569-73. PubMed ID: 23721099
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a "real-world" study: the Royal Marsden Hospital experience.
Sriskandarajah P; Pawlyn C; Mohammed K; Dearden CE; Davies FE; Morgan GJ; Boyd KD; Kaiser MF
Leuk Lymphoma; 2017 Feb; 58(2):494-497. PubMed ID: 27439571
[No Abstract] [Full Text] [Related]
20. Pomalidomide-Responsive Extramedullary Myeloma Relapsed after Allogeneic Hematopoietic Transplant and Refractory to Multiple Lines of Chemotherapy.
Leotta S; Pirosa MC; Markovic U; Scalise L; Bulla A; Sapienza G; Di Giorgio MA; Martino EA; Curto Pelle A; Leotta V; Milone G; Cupri A; Vaddinelli D; Villari L; Conticello C; Milone G
Chemotherapy; 2019; 64(2):110-114. PubMed ID: 31533095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]